Latest news with #CarlHansen
National Post
08-05-2025
- Business
- National Post
AbCellera Reports Q1 2025 Business Results
Article content VANCOUVER, British Columbia — AbCellera (Nasdaq: ABCL) today announced financial results for the first quarter of 2025. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated. Article content Article content 'After completion of a successful first quarter, we are excited to introduce ABCL635 as a potential first-in-class antibody for the non-hormonal treatment of vasomotor symptoms (hot flashes) associated with menopause. ABCL635 is positioned as a next-generation neurokinin 3 receptor (NK3R) antagonist with an improved safety profile and convenient dosing regimen. If successful, we believe it has the potential to be a highly differentiated product in a large and established market,' said Carl Hansen, Ph.D., founder and CEO of AbCellera. 'We ended the quarter with over $800 million in available liquidity to execute on our strategy and anticipate starting Phase 1 clinical trials for both ABCL635 and ABCL575 in the second half of 2025.' Article content Earned $4.2 million in total revenue. Generated a net loss of $45.6 million, compared to net loss of $40.6 million in 2024. Reached a cumulative total of 97 partner-initiated program starts with downstreams. Maintained a cumulative total of 16 molecules to have reached the clinic. Article content AbCellera started discovery on an additional partner-initiated program with downstreams to reach a cumulative total of 97 partner-initiated program starts with downstreams in Q1 2025 (up from 90 on March 31, 2024). AbCellera's partners have advanced a cumulative total of 16 molecules into the clinic (up from 13 on March 31, 2024). Article content Discussion of Q1 2025 Financial Results Article content Revenue – Total revenue was $4.2 million, compared to $10.0 million in Q1 2024. In both periods, the majority of revenues were research fees generated by our partnerships. Research & Development (R&D) Expenses – R&D expenses were $42.5 million, compared to $39.3 million in Q1 2024, reflecting growing investments in internal programs. Sales & Marketing (S&M) Expenses – S&M expenses were $2.8 million, compared to $3.4 million in Q1 2024. General & Administrative (G&A) Expenses – G&A expenses were $16.2 million, compared to $17.4 million in Q1 2024. Net Loss – Net loss of $45.6 million, or $(0.15) per share on a basic and diluted basis, compared to net loss of $40.6 million, or $(0.14) per share on a basic and diluted basis, in Q1 2024. Liquidity – $633 million of total cash, cash equivalents, and marketable securities and approximately $178 million in available non-dilutive government funding, bringing total available liquidity to approximately $810 million to execute on AbCellera's strategy. Article content AbCellera will host a conference call and live webcast to discuss these results today at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time). Article content The live webcast of the earnings conference call can be accessed on the Events and Presentations section of AbCellera's Investor Relations website. A replay of the webcast will be available through the same link following the conference call. Article content About AbCellera Biologics Inc. Article content AbCellera (Nasdaq: ABCL) discovers and develops antibody medicines for indications across therapeutic areas including cancer, metabolic and endocrine conditions, and autoimmune disorders. AbCellera integrates technology, data science, infrastructure, and interdisciplinary teams to solve the most challenging antibody discovery problems. AbCellera is focused on advancing an internal pipeline of first-in-class and best-in-class programs and collaborating on innovative drug development programs with partners. For more information, please visit Article content We regularly review the following key business metrics to evaluate our business, measure our performance, identify trends affecting our business, formulate financial projections, and make strategic decisions. We believe that the following metrics are important to understand our current business. These metrics may change or may be substituted for additional or different metrics as our business develops. Article content Partner-initiated program starts with downstreams represent the number of unique partner-initiated programs where we stand to participate financially in downstream success for which we have commenced the discovery effort. The discovery effort commences on the later of (i) the day on which we receive sufficient reagents to start discovery of antibodies against a target and (ii) the day on which the kick-off meeting for the program is held. We view this metric as an indication of the selection and initiation of projects by our partners and the resulting potential for near-term payments. Cumulatively, partner-initiated program starts with downstream participation indicate our total opportunities to earn downstream revenue from milestone fees and royalties (or royalty equivalents) in the mid- to long-term. Article content Molecules in the clinic represent the count of unique molecules for which an Investigational New Drug, or IND, New Animal Drug, or equivalent under other regulatory regimes, application has reached 'open' status or has otherwise been approved based on an antibody that was discovered either by us or by a partner using licensed AbCellera technology. Where the date of such application approval is not known to us, the date of the first public announcement of a clinical trial will be used for the purpose of this metric. We view this metric as an indication of our near- and mid-term potential revenue from milestone fees and potential royalty payments in the long term. Article content AbCellera Forward-Looking Statements Article content This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management's current beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations. Article content In some cases, you can identify forward-looking statements by the words 'may,' 'will,' 'could,' 'would,' 'should,' 'expect,' 'intend,' 'plan,' 'anticipate,' 'believe,' 'estimate,' 'predict,' 'project,' 'potential,' 'continue,' 'ongoing' or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under 'Risk Factors,' 'Management's Discussion and Analysis of Financial Condition and Results of Operations' and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law. Article content Article content Article content Article content Article content Article content
Tatler Asia
02-05-2025
- Entertainment
- Tatler Asia
Home tour: A Parisian apartment blending 18th-century grandeur with curated antiques
Above The bright and cheerful apartment with pops of vibrancy and drama Above The 18th-century carved gilded mirror atop the fireplace Above The Venetian snake-design table and marble apple Although the property had undergone previous renovations, and Silvestry's design team was brought in to decorate the modernised space, they faced an extraordinarily tight timeline due to restrictions implemented in anticipation of the Olympic Games held in July of the previous year. 'Given the scale of the project, even minor delays could cause a ripple effect, so keeping everything on track required precise scheduling and constant communication,' divulges Silvestry, who was hired in April before receiving the keys in June on the day the purchase was finalised. Don't miss: 7 luxury boutique hotels in Paris for the stylish Olympics 2024 spectator Above The 18th-century Florentine painting from Yveline Antiques in the dining area Above The antique chandelier's delicate design plays off the glamorous architectural features Above First edition Wishbone chairs by Carl Hansen provides a contemporary respite She adds: 'While working within the constraints of available stock items, and facing delivery delays due to restricted access to the area caused by preparations for the Olympic Games, we took a proactive approach by maintaining flexibility in our design selections, ensuring that every design decision stayed true to our vision.' Read more: Home tour: A black-and-white home in Colmar inspired by the Eiffel Tower and Statue of Liberty Despite these challenges, Silvestry completed the project in just three weeks, delivering a bright and cheerful apartment with dramatic elements that exceeded the clients' expectations. 'The space is beautiful, and I love a good challenge,' she reflects. Above The blue-toned kitchen area with wooden herringbone-patterned flooring and white cabinetry Above Family-friendly surfaces with enhanced charm overtime while allowing carefree enjoyment Above Henry Walter Klein's midcentury teak chairs with reupholstered in bright blue fabric by Pierre Frey Based in Paris, the interior designer enjoys access to exquisite antique pieces from the Marché aux Puces and other specialty markets throughout the city. A serendipitous discovery of a stunning gold and green mirror and chandelier from Lila K Antiques inspired the apartment's design direction. 'The green was already within the apartment palette and the chandelier's delicate design was as glamorous as the architectural features,' Silvestry explains. See also: Inside Chee Soon & Fitzgerald: A little shop of treasures in Redfern, Sydney Above One of the bathrooms with fixtures reminiscent of the building's illustrious past Above Another bathroom is fitted with a more contemporary vanity and colour In the freshly repainted living room, the 18th-century carved gilded mirror now crowns the fireplace. Creating visual harmony, an 18th-century Florentine painting from Yveline Antiques depicting Adam receiving the forbidden fruit adorns the main wall. 'To add a sense of intrigue and humour, the painting was complemented with a pair of stunning Venetian snake-design tables and an 18th-century marble apple,' she reveals. Don't miss: Home tour: Inside Kai-yin Lo's Hong Kong home—a treasure trove of antiques and her prized jewellery design Above Refreshing hues of blue in the guest room with arched doorways Furthermore, for the dining area, Silvestry also managed to find first edition Wishbone chairs by Carl Hansen alongside a complementary 1960s Scandinavian-style table crafted in France. Meanwhile, Henry Walter Klein's midcentury teak chairs, reupholstered in Pierre Frey fabric, anchor the breakfast nook in the kitchen with its wooden herringbone flooring, lending character and authenticity to the classic design. Read more: 5 interior designer tips for kid-friendly bedrooms that grow with your children 'We also reupholstered some swivel chairs with Dedar fabric–both outdoor fabrics for long-lasting, heavy-duty use,' Silvestry notes. 'Considering their young children, we selected surfaces that develop a beautiful patina over time, enhancing the charm while allowing carefree enjoyment.' Above The primary suite through the ornate architrave and French doors Above The children's room adheres to the overall green colour palette 'My favourite aspect was having the opportunity to enhance the beautiful volumes and extraordinary Parisian space of the living room and kitchen,' the interior designer concludes. 'The lofty ceilings and intricate architectural details provided the perfect foundation for restoring some of the home's original grandeur through a refined yet unexpected interplay of textures–making this project one of my favourites.' NOW READ Step inside these 5 renovated Parisian homes with stunning interiors 7 iconic cantilever chairs that shaped modern furniture How 'interiors disruptor' Alex Alonso embraces colourful maximalism in summer homes Credits Photography: Benoît Linero
Yahoo
18-02-2025
- Business
- Yahoo
One AbCellera Biologics Insider Raised Their Stake In The Previous Year
Viewing insider transactions for AbCellera Biologics Inc.'s (NASDAQ:ABCL ) over the last year, we see that insiders were net buyers. This means that a larger number of shares were purchased by insiders in relation to shares sold. Although we don't think shareholders should simply follow insider transactions, logic dictates you should pay some attention to whether insiders are buying or selling shares. Check out our latest analysis for AbCellera Biologics The CEO, President & Chairperson Carl Hansen made the biggest insider purchase in the last 12 months. That single transaction was for US$740k worth of shares at a price of US$2.61 each. We do like to see buying, but this purchase was made at well below the current price of US$3.27. Because the shares were purchased at a lower price, this particular buy doesn't tell us much about how insiders feel about the current share price. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. By clicking on the graph below, you can see the precise details of each insider transaction! There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of undervalued small cap companies that insiders are buying. I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. AbCellera Biologics insiders own about US$220m worth of shares (which is 23% of the company). Most shareholders would be happy to see this sort of insider ownership, since it suggests that management incentives are well aligned with other shareholders. The fact that there have been no AbCellera Biologics insider transactions recently certainly doesn't bother us. On a brighter note, the transactions over the last year are encouraging. It would be great to see more insider buying, but overall it seems like AbCellera Biologics insiders are reasonably well aligned (owning significant chunk of the company's shares) and optimistic for the future. While it's good to be aware of what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. You'd be interested to know, that we found 1 warning sign for AbCellera Biologics and we suggest you have a look. But note: AbCellera Biologics may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt. For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
